

Christi J Van Asperen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3083151/publications.pdf>

Version: 2024-02-01

155
papers

11,898
citations

36203

51
h-index

31759

101
g-index

159
all docs

159
docs citations

159
times ranked

15564
citing authors

#	ARTICLE	IF	CITATIONS
1	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
2	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	9.4	960
3	Breast Cancer Risk Genes Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	13.9	532
4	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	9.4	513
5	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
6	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. <i>Nature Genetics</i> , 2009, 41, 585-590.	9.4	434
7	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	428
8	Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. <i>PLoS Genetics</i> , 2008, 4, e1000054.	1.5	315
9	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
10	TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. <i>Journal of Medical Genetics</i> , 2010, 47, 421-428.	1.5	254
11	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
12	Targeted Prostate Cancer Screening in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	0.9	195
13	Exposure to diagnostic radiation and risk of breast cancer among carriers of <i>BRCA1/2</i> mutations: retrospective cohort study (GENE-RAD-RISK). <i>BMJ</i> , The, 2012, 345, e5660-e5660.	3.0	186
14	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction. <i>Cancer Research</i> , 2010, 70, 9742-9754.	0.4	169
15	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	1.4	152
16	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	0.8	152
17	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in <i>BRCA2</i> Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	0.9	148
18	Next-Generation Diagnostics: Gene Panel, Exome, or Whole Genome?. <i>Human Mutation</i> , 2015, 36, 648-655.	1.1	124

#	ARTICLE	IF	CITATIONS
19	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
20	The counselees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. <i>Psycho-Oncology</i> , 2008, 17, 822-830.	1.0	112
21	A genome wide linkage search for breast cancer susceptibility genes. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 646-655.	1.5	111
22	Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 723-733.	1.1	111
23	Deletions spanning the neurofibromatosis type 1 gene: Implications for genotype-phenotype correlations in neurofibromatosis type 1?. , 1997, 9, 458-464.		109
24	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. <i>Human Molecular Genetics</i> , 2016, 25, 2256-2268.	1.4	106
25	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	5.8	105
26	The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. <i>Cancer Cell</i> , 2011, 19, 273-282.	7.7	104
27	Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019, 40, 1557-1578.	1.1	102
28	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv219.	3.0	99
29	Intronic variants inBRCA1andBRCA2that affect RNA splicing can be reliably selected by splice-site prediction programs. <i>Human Mutation</i> , 2009, 30, 107-114.	1.1	97
30	BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. <i>Journal of Medical Genetics</i> , 2012, 49, 525-532.	1.5	97
31	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014, 16, 3419.	2.2	97
32	Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2 Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles. <i>PLoS ONE</i> , 2013, 8, e55681.	1.1	95
33	<i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	1.4	91
34	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
35	Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 381-390.	1.1	88
36	Clinical Characteristics Affect the Impact of an Uninformative DNA Test Result: The Course of Worry and Distress Experienced by Women Who Apply for Genetic Testing for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3672-3677.	0.8	84

#	ARTICLE	IF	CITATIONS
37	Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 235-244.	1.1	79
38	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	2.6	76
39	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. <i>Seminars in Oncology</i> , 2017, 44, 187-197.	0.8	76
40	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2789-2799.	0.4	75
41	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. <i>Journal of Medical Genetics</i> , 2014, 51, 98-107.	1.5	74
42	Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>European Journal of Cancer</i> , 2017, 82, 219-227.	1.3	71
43	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321.	1.4	68
44	Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. <i>Breast Cancer Research</i> , 2007, 9, R78.	2.2	64
45	Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. <i>European Journal of Cancer</i> , 2016, 61, 137-145.	1.3	64
46	Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2 result. <i>Psycho-Oncology</i> , 2012, 21, 29-42.	1.0	60
47	Body weight and risk of breast cancer in BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 193-202.	1.1	59
48	Genetic testing for familial/hereditary breast cancer – comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. <i>Journal of Community Genetics</i> , 2011, 2, 53-69.	0.5	59
49	The functional impact of variants of uncertain significance in BRCA2. <i>Genetics in Medicine</i> , 2019, 21, 293-302.	1.1	58
50	A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example. <i>BMC Cancer</i> , 2009, 9, 211.	1.1	57
51	What's the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer. <i>Genetics in Medicine</i> , 2005, 7, 239-245.	1.1	55
52	Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress. <i>Patient Education and Counseling</i> , 2007, 65, 58-68.	1.0	55
53	A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships. <i>Psycho-Oncology</i> , 2007, 16, 320-328.	1.0	52
54	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	2.9	52

#	ARTICLE	IF	CITATIONS
55	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. <i>Scientific Reports</i> , 2018, 8, 6574.	1.6	51
56	Comprehensive Mutation Analysis of <i>PMS2</i> in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome. <i>Human Mutation</i> , 2016, 37, 1162-1179.	1.1	50
57	Rare variants in <i>XRCC2</i> as breast cancer susceptibility alleles: Table A1. <i>Journal of Medical Genetics</i> , 2012, 49, 618-620.	1.5	49
58	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	1.1	49
59	Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. <i>European Journal of Cancer</i> , 2016, 69, 127-134.	1.3	49
60	A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. <i>Familial Cancer</i> , 2011, 10, 87-96.	0.9	48
61	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
62	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
63	A method to assess the clinical significance of unclassified variants in the <i>BRCA1</i> and <i>BRCA2</i> genes based on cancer family history. <i>Breast Cancer Research</i> , 2009, 11, R8.	2.2	45
64	The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective study. <i>Psycho-Oncology</i> , 2007, 16, 1121-1129.	1.0	44
65	Effectiveness and cost-effectiveness of meaning-centered group psychotherapy in cancer survivors: protocol of a randomized controlled trial. <i>BMC Psychiatry</i> , 2014, 14, 22.	1.1	44
66	Endometrial Cancer Risk in Women With Germline <i>BRCA1</i> or <i>BRCA2</i> Mutations: Multicenter Cohort Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1203-1211.	3.0	44
67	Variants of Uncertain Clinical Significance as a Result of BRCA1/2 Testing: Impact of an Ambiguous Breast Cancer Risk Message. <i>Genetic Testing and Molecular Biomarkers</i> , 2004, 8, 235-239.	1.7	42
68	Risk Estimation for Healthy Women from Breast Cancer Families: New Insights and New Strategies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 87-93.	1.1	41
69	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015, 24, 2966-2984.	1.4	40
70	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
71	<i>MUTYH</i> gene variants and breast cancer in a Dutch case-control study. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 219-227.	1.1	38
72	Identification and characterization of novel associations in the <i>CASP8/ALS2CR12</i> region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	1.4	38

#	ARTICLE	IF	CITATIONS
73	Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing. <i>European Journal of Cancer</i> , 2007, 43, 71-77.	1.3	36
74	A functional assay-based procedure to classify mismatch repair gene variants in Lynch syndrome. <i>Genetics in Medicine</i> , 2019, 21, 1486-1496.	1.1	36
75	Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. <i>Breast Cancer Research</i> , 2011, 13, R72.	2.2	35
76	The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters. <i>Psycho-Oncology</i> , 2013, 22, 902-910.	1.0	35
77	Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families. <i>Journal of Medical Genetics</i> , 2019, 56, 581-589.	1.5	35
78	Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. <i>Clinical Cancer Research</i> , 2019, 25, 7517-7526.	3.2	34
79	Family communication matters: The impact of telling relatives about unclassified variants and uninformative DNA-test results. <i>Genetics in Medicine</i> , 2011, 13, 333-341.	1.1	33
80	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky023.	1.4	33
81	Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families. <i>International Journal of Cancer</i> , 2019, 144, 2453-2464.	2.3	33
82	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 4732-4747.	1.4	32
83	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Modern Pathology</i> , 2017, 30, 509-518.	2.9	32
84	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
85	Exploring the short-term impact of DNA-testing in breast cancer patients: The counselees' perception matters, but the actual BRCA1/2 result does not. <i>Patient Education and Counseling</i> , 2012, 86, 239-251.	1.0	31
86	Classification and Clinical Management of Variants of Uncertain Significance in High Penetrance Cancer Predisposition Genes. <i>Human Mutation</i> , 2016, 37, 331-336.	1.1	31
87	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
88	CHEK2*1100delC homozygosity in the Netherlands prevalence and risk of breast and lung cancer. <i>European Journal of Human Genetics</i> , 2014, 22, 46-51.	1.4	29
89	Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling. <i>PLoS ONE</i> , 2013, 8, e55734.	1.1	29
90	Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies. <i>BMC Genomics</i> , 2007, 8, 299.	1.2	26

#	ARTICLE	IF	CITATIONS
91	Feeling at risk: How women interpret their familial breast cancer risk. <i>American Journal of Medical Genetics Part A</i> , 2004, 131A, 42-49.	2.4	25
92	Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines. <i>European Journal of Human Genetics</i> , 2005, 13, 525-527.	1.4	25
93	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. <i>Breast Cancer Research</i> , 2010, 12, R102.	2.2	25
94	A counselee-oriented perspective on risk communication in genetic counseling: Explaining the inaccuracy of the counselees' risk perception shortly after BRCA1/2 test result disclosure. <i>Genetics in Medicine</i> , 2011, 13, 800-811.	1.1	25
95	Homozygosity for aCHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype. <i>Journal of Pathology</i> , 2005, 206, 198-204.	2.1	24
96	A 7 Mb region within 11q13 may contain a high penetrance gene for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 151-159.	1.1	23
97	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	1.1	23
98	Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2. <i>Genetics in Medicine</i> , 2020, 22, 1355-1365.	1.1	23
99	Do BRCA1/2 mutation carriers have an earlier onset of natural menopause?. <i>Menopause</i> , 2016, 23, 903-910.	0.8	22
100	Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers. <i>British Journal of Cancer</i> , 2018, 119, 357-363.	2.9	22
101	Variants of Uncertain Significance in <i>BRCA1</i> and <i>BRCA2</i> assessment of in silico analysis and a proposal for communication in genetic counselling. <i>Journal of Medical Genetics</i> , 2013, 50, 74-79.	1.5	21
102	Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program. , 2015, , .		20
103	Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment. <i>Psycho-Oncology</i> , 2013, 22, 1167-1176.	1.0	19
104	Meaning-centered group psychotherapy in cancer survivors: a feasibility study. <i>Psycho-Oncology</i> , 2014, 23, 827-831.	1.0	19
105	The <i>BRCA2</i> c.68-7T>A variant is not pathogenic: A model for clinical calibration of spliceogenicity. <i>Human Mutation</i> , 2018, 39, 729-741.	1.1	19
106	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
107	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	5.8	19
108	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19

#	ARTICLE	IF	CITATIONS
109	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. <i>Genome Medicine</i> , 2022, 14, 51.	3.6	19
110	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. <i>Human Genetics</i> , 2011, 130, 685-699.	1.8	18
111	Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 600-611.	1.2	18
112	Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort. <i>Genetics in Medicine</i> , 2007, 9, 173-179.	1.1	17
113	Design of the BRISC study: a multicentre controlled clinical trial to optimize the communication of breast cancer risks in genetic counselling. <i>BMC Cancer</i> , 2008, 8, 283.	1.1	17
114	The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study. <i>Familial Cancer</i> , 2019, 18, 137-146.	0.9	17
115	How women with a family history of breast cancer and their general practitioners act on genetic advice in general practice: prospective longitudinal study. <i>BMJ: British Medical Journal</i> , 2001, 322, 26-27.	2.4	16
116	Genome-wide linkage scan in Dutch hereditary non-BRCA1/2 breast cancer families identifies 9q21 as a putative breast cancer susceptibility locus. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 947-956.	1.5	16
117	Putting it all behind: long-term psychological impact of an inconclusive DNA test result for breast cancer. <i>Genetics in Medicine</i> , 2008, 10, 745-750.	1.1	16
118	Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: general practitioners' and breast surgeons' current practice and preferred practice responsibilities. <i>Journal of Community Genetics</i> , 2014, 5, 69-79.	0.5	16
119	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
120	Recommendations for reporting results of diagnostic genomic testing. <i>European Journal of Human Genetics</i> , 2022, 30, 1011-1016.	1.4	15
121	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. <i>Carcinogenesis</i> , 2015, 36, 256-271.	1.3	14
122	Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-making. <i>Journal of Genetic Counseling</i> , 2019, 28, 533-542.	0.9	14
123	Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-analysis of 58,580 Colorectal Carcinomas. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e496-e507.	2.4	14
124	Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study. <i>International Journal of Cancer</i> , 2014, 135, 2940-2949.	2.3	13
125	CM-Score: a validated scoring system to predict <i>CDKN2A</i> germline mutations in melanoma families from Northern Europe. <i>Journal of Medical Genetics</i> , 2018, 55, 661-668.	1.5	13
126	Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene <i>XRCC2</i> . <i>Human Mutation</i> , 2016, 37, 914-925.	1.1	12

#	ARTICLE	IF	CITATIONS
127	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	2.9	12
128	A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient. <i>Laboratory Investigation</i> , 2004, 84, 191-202.	1.7	11
129	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. <i>PLoS ONE</i> , 2012, 7, e35706.	1.1	11
130	Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2482-2491.	1.1	11
131	An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. <i>Genetics in Medicine</i> , 2019, 21, 2706-2712.	1.1	11
132	The effectiveness of a graphical presentation in addition to a frequency format in the context of familial breast cancer risk communication: a multicenter controlled trial. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, 55.	1.5	10
133	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. <i>Genetics in Medicine</i> , 2022, 24, 119-129.	1.1	10
134	A family history of breast cancer will not predict female early onset breast cancer in a population-based setting. <i>BMC Cancer</i> , 2008, 8, 203.	1.1	9
135	Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1251-1258.	1.1	9
136	Validation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists. <i>PLoS ONE</i> , 2017, 12, e0178447.	1.1	9
137	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). <i>JMIR Research Protocols</i> , 2021, 10, e24414.	0.5	9
138	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 202.e19-202.e28.	0.8	8
139	Association between a 46-SNP Polygenic Risk Score and melanoma risk in Dutch patients with familial melanoma. <i>Journal of Medical Genetics</i> , 2021, 58, 760-766.	1.5	8
140	Disentangling the Babylonian speech confusion in genetic counseling: An analysis of the reliability and validity of the nomenclature for BRCA1/2 DNA-test results other than pathogenic. <i>Genetics in Medicine</i> , 2009, 11, 742-749.	1.1	6
141	Urologists' and GPs' knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands. <i>Familial Cancer</i> , 2012, 11, 195-200.	0.9	6
142	Value-based healthcare in Lynch syndrome. <i>Familial Cancer</i> , 2013, 12, 347-354.	0.9	6
143	General Practitioners and Breast Surgeons in France, Germany, Netherlands and the UK show variable breast cancer risk communication profiles. <i>BMC Cancer</i> , 2015, 15, 243.	1.1	6
144	Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making. <i>Journal of Community Genetics</i> , 2021, 12, 101-110.	0.5	6

#	ARTICLE	IF	CITATIONS
145	Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. <i>Breast</i> , 2022, 61, 98-107.	0.9	6
146	Breast Cancer Susceptibilityâ€”Towards Individualised Risk Prediction. <i>Current Genetic Medicine Reports</i> , 2019, 7, 124-135.	1.9	4
147	<p>Do Preferred Risk Formats Lead to Better Understanding? A Multicenter Controlled Trial on Communicating Familial Breast Cancer Risks Using Different Risk Formats</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 333-342.	0.8	4
148	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	2.3	4
149	Efficacy of risk-reducing mastectomy (RRM) on overall survival (OS) in BRCA1/2-associated breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1502-1502.	0.8	3
150	Breast surgeons' attitudes towards bilateral risk-reducing mastectomy: A National Survey of American Surgeons.. <i>Journal of Clinical Oncology</i> , 2015, 33, 25-25.	0.8	3
151	Genetic clinicians' confidence in <scp>BOADICEA</scp> comprehensive breast cancer risk estimates and counselees' psychosocial outcomes: A prospective study. <i>Clinical Genetics</i> , 2022, 102, 30-39.	1.0	3
152	Clustering of known low and moderate risk alleles rather than a novel recessive highâ€risk gene in nonâ€BRCA1 /2 sib trios affected with breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 2708-2716.	2.3	2
153	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	1.6	2
154	Response to Nahshon and Lavie. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	0
155	Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations. , 2020, , .		0